Innovent Biologics Rallies on $1.1 Billion Spero Licensing Pact

Under the terms of the agreement, Innovent secures upfront payments and future milestone rewards, alongside tiered royalties on net sales. Spero gains exclusive global access to IBI355, a monoclonal antibody targeting autoimmune conditions, while Innovent maintains rights within Greater China. Spero expects to launch a Phase 2 trial for IgG4-related disease by the second quarter of 2027, complementing Innovent’s own planned trial for Sjögren’s disease in China earlier that year.

This transaction reflects a broader industry pattern where global pharmaceutical majors increasingly tap into Chinese innovation. Recent multi-billion dollar deals involving Dizal and Sino Biopharmaceutical with AstraZeneca underscore this trend. Citi analysts noted the deal validates Innovent’s autoimmune franchise, suggesting that such cross-border collaborations remain resilient despite geopolitical friction. Innovent’s stock settled 7.2% higher following the announcement, extending its year-to-date gains to approximately 26%.